Abstract. The aim of the present study was to detect DACT1 expression levels in the lungs of children with asthma, and to investigate its role and molecular mechanisms in regulating the expression of inflammatory factors in RAW264.7 cells. DACT1, DACT2 and DACT3 expression was analyzed in biopsy specimens from 10 cases of newly diagnosed children with asthma and 10 healthy controls by reverse transcription-quantitative polymerase chain reaction, and their expression was confirmed in RAW264.7 cells. DACT1 expression was silenced by small interfering RNA or enhanced by transfection of pcDNA-3.1-DACT1 in RAW264.7 cells, and expression of β-catenin and inflammatory factors, interleukin (IL) 5, IL6 and IL13, was analyzed. Nuclear translocation of β-catenin was detected by western blot analysis, and the effect of DACT1 on β-catenin was investigated with rescue experiments. Regulation of the Wnt signaling pathway by DACT1 and β-catenin was analyzed in RAW264.7 cells after recombinant Wnt5A stimulation. DACT1, DACT2 and DACT3 were significantly upregulated in specimens from children with asthma compared with controls (P<0.05) and the expression of DACT1 was significantly more increased compared with DACT2 and DACT3 (P<0.05). Inhibition of DACT1 expression significantly suppressed IL5, IL6 and IL13 mRNA expression levels compared with the control (P<0.05), while upregulated DACT1 expression significantly increased IL5, IL6 and IL13 mRNA expression (P<0.05). DACT1 inhibited the expression and nuclear translocation of β-catenin, while overexpression of β-catenin significantly inhibited the biological function of DACT1 (P<0.05). Overexpression of β-catenin also significantly suppressed the upregulation of IL5, IL6 and IL13 mRNA induced by pcDNA3.1-DACT1 transfection (P<0.05). Following the addition of Wnt5A, overexpression of DACT1 inhibited the expression and nuclear translocation of β-catenin, and upregulated IL5, IL6 and IL13 mRNA expression. In conclusion, DACT1 was indicated to be upregulated in lung tissues from children with asthma, which could induce higher pro-inflammatory factor expression. DACT1 may act via inhibiting the expression and nuclear translocation of β-catenin, a factor in the Wnt signaling pathway. The present results suggested that DACT1 may be a potential target for the treatment of asthma.
Introduction
Bronchial asthma (asthma) is an airway chronic persistent inflammatory disease in the respiratory tract. It is accompanied by increased airway reactivity that involves a variety of inflammatory cells (including T lymphocytes, eosinophils, neutrophils and mast cells), structural cells (including smooth muscle cells and respiratory epithelial cells) and other cell types, and acute attacks of this disease can endanger the patient's life (1) (2) (3) . A recent study indicated that the incidence of asthma in children increases year by year, which has attracted the attention of researchers worldwide (4) . Currently, long-term inhaled corticosteroid treatment is the principal method of treating asthma clinically, which alleviates the symptoms of the condition. However, hormone resistance or dependence, and drug-induced side effects of hormones, such as femoral head necrosis and growth suppression, may occur simultaneously (5, 6) . Asthma is primarily characterized by chronic airway inflammation, airway hyperresponsiveness and airway irreversible remodeling (7, 8) , among which airway remodeling is directly related to the prognosis of patients with asthma. Recent studies confirmed the involvement of inflammatory, smooth muscle and epithelial cells in this process; however, the molecular mechanism involved remains unclear (9, 10) .
DACT1 is a member of the Dapper family, which includes three genes: DACT1, DACT2 and DACT3 (11) . As a tumor suppressor, DACT1 is downregulated in multiple tumor types, such as liver, colon and breast cancer (12) . It has been demonstrated that DACT1 functions in the development of tumors primarily by regulating signaling pathways, such as Wnt and the c-Jun N-terminal kinase pathway (13) (14) (15) . For instance, DACT1 binds to disheveled homolog 1 (Dvl1) to induce the degradation of Dvl1 and the subsequent inhibition of the Wnt/β-catenin pathway (16) . DACT1 may also bind to Dvl2, affecting cell movement ability by regulating cell polarity (17) . The Wnt/β-catenin signaling pathway is involved in the regulation of numerous physiological and pathological processes, and is closely associated with multiple diseases. Previous studies have indicated that the Wnt/β-catenin pathway is associated with lung development, pulmonary fibrosis, airway remodeling and inflammation (18, 19) . For example, TGF-β1 stimulation of human lung fibroblast cells upregulates Wnt pathway-related gene expression, such as the expression of Wnt5b, frizzled-8 and Dvl3, and induces differentiation of fibroblasts into myofibroblasts, and these effects could be alleviated by inhibition of the Wnt signaling pathway (20) . In addition, the Wnt signaling pathway may inhibit IL6 expression in asthma effector cells, thereby reducing the local inflammatory response (21) . Based on these findings, it was proposed that DACT1 may be involved in asthma airway inflammation via regulation of the Wnt signaling pathway. In the present study, the macrophage cell line, RAW264.7, was used to investigate the regulatory mechanisms and biological effects of DACT1 on the Wnt signaling pathway.
Materials and methods
Patients. A total of 10 child patients (mean age, 12 years; 3 males and 7 females) with asthma that were first diagnosed by electronic bronchoscope and 10 healthy controls were recruited from the First People's Hospital of Jining (Jining, China) between November 2013 and January 2015. The patients were admitted to the Department of Pediatrics, The First People's Hospital of Jining (Jining, China) and the healthy controls (mean age, 15.5±1.0 years; 6 males and 4 females) were recruited at the Physical Examination Center of the First People's Hospital of Jining. In these controls, there was no history of chronic diseases, organic disease, no history of prolonged medication use and no acute diseases were indicated during physical examination. Patients with asthma were children who were first diagnosed with mild or medium asthma, and none of the subjects accepted hormone treatment in the 4 weeks prior to diagnosis. Lung tissues from patients (pathological tissues) and healthy controls (normal tissues) were collected and stored in -80˚C following freezing by liquid nitrogen. Prior to collection of tissues, written informed consent was obtained from the patients' families and the study was approved by the Ethics Review Board of the First People's Hospital of Jining.
Cell culture and transfection. Mouse RAW264.7 cells were purchased from the Cell Center of Chinese Academy of Science (Shanghai, China) and cultured in high glucose Dulbecco's modified Eagle's medium (DMEM; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and 1% penicillin-streptomycin. Cultures were incubated in a humidified atmosphere with 5% CO 2 at 37˚C and passaged every 24-48 h when confluence reached 90%.
A total of 2x10 5 RAW264.7 cells were inoculated into a 24-well plate with DMEM supplemented with 10% FBS without antibiotics at 37˚C. When the confluence reached 70%, cells were used for transfection. A total of 2x10 5 cells were transfected with 25 pmol of mature DACT1 small interfering (si)RNA (siR-DACT1; Hanheng Biotechnology Co., Ltd., Shanghai, China) (forward, 5'-AGU UCA AUU GCU UUC UUA GCA-3' and reverse, 5'-CUA AGA AAG CAA UUG AAC UGU-3') using Lipofectamine 2000 (Thermo Fisher Scientific, Inc.), according to the manufacturer's instructions. As a control, RAW264.7 cells (2x10 5 ) were transfected with negative control siRNA (Hanheng Biotechnology Co., Ltd.) without specifically targeting any human gene products. For overexpression of the DACT1 gene, cells were transfected with 300 µg pcDNA3.1-DACT1, pcDNA3.1-β-catenin or an empty vector (Hanheng Biotechnology Co., Ltd.) using Lipofectamine 2000. Cells were collected at 48 h post-transfection for further experiments. Cells transfected with siRNA negative control were considered the NC group and cells transfected with pcDNA3.1 empty vector were considered the empty vector group.
RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) assay.
Total RNA was extracted from cells and tissues using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's instructions. A total of 1 ml TRIzol reagent was added to 100 mg tissue or a single cell layer in a 10-cm culture plate. RNA was reverse transcribed into cDNA using a Takara PrimeScript RT Reagent kit (Takara Biotechnology Co., Ltd., Dalian, China), according to the manufacturer's instructions. Subsequently, qPCR was performed using a SYBR PrimeScript RT-PCR kit (Takara Biotechnology Co., Ltd.), according to the manufacturer's instructions. The expression of GAPDH was used as an internal control for mRNA. The reaction mixture was incubated for 1 cycle at 95˚C for 10 min, followed by 40 cycles at 95˚C for 30 sec and 60˚C for 30 sec. Primers used for amplification are demonstrated in Table I . The relative expression levels were evaluated using the 2 -ΔΔCq method (22) and repeated for three times. Table I . Primers used for quantitative polymerase chain reaction.
Primers
Primer sequence
Western blot analysis. Lung tissues from patients were ground in liquid nitrogen and 100 mg of tissue was used for RNA extraction. A total of 1x10 6 RAW264.7 cells were collected at 48 h after transfection. Pre-cooled radioimmunoprecipitation assay lysis buffer including phenylmethylsulfonyl fluoride (Thermo Fisher Scientific, Inc.) was added to the tissues and cells and incubated on ice for 5 min. The supernatant was collected by centrifugation at 12,000 x g for 10 min at 4˚C. Nuclear β-catenin protein was extracted using a nucleus protein extract kit (cat. no. KGBSP002; Jiangsu KeyGen Biotech Co., Ltd., Nanjing, China), according to the manufacturer's instructions. Protein was quantified using the BCA method. A total of 5 µl protein/well was separated by 10% SDS-PAGE and the proteins were transferred onto polyvinylidene fluoride membranes. Following blocking with 5% non-fat milk for 1 h at room temperature, expression of DACT1 and β-catenin was detected with the following antibodies at 4˚C overnight: Rabbit anti-DACT1 (1:1,000; cat. no. ab47473), rabbit anti-β-catenin (1:1,000; cat. no. ab16502) (both from Abcam, Cambridge, MA, USA), rabbit anti-mouse (cat. no. AH433; 1:3,000) and mouse anti-GAPDH (cat. no. A2016; 1:5,000) (both from Beyotime Institute of Biotechology, Beijing, China). Following washing with PBST for three times (15 min each time), the membrane was incubated with goat anti-rabbit IgG H&L (HRP) (cat. no. ab6721; 1:5,000) or rabbit anti-mouse IgG H&L (HRP) (cat. no. ab6728; Abcam, Cambridge, UK) at room temperature for 1 h. Finally, the membrane was developed using enhanced chemiluminescence reagents (Beyotime Institute of Biotechnology). Western blot images were analyzed using Image Lab software 5.2.1 (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Each experiment was repeated for three times and the expression levels of DACT1 and β-catenin were normalized against GAPDH.
Statistical analysis. Data were expressed as the mean ± standard deviation. Statistical significance was evaluated using the paired t-test on SPSS version 16.0 software (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.
Results

Expression of DACT in children with asthma.
To evaluate the expression of DACT genes in children with asthma, DACT mRNA and DACT protein expression levels were analyzed using RT-qPCR and western blot analysis, respectively. As demonstrated in Fig. 1A , DACT1, DACT2 and DACT3 mRNA levels were significantly upregulated in tissues from asthmatic patients compared with normal controls (P<0.05). The results of the western blot analysis were consistent with this, demonstrating significant upregulation of DACT1, DACT2 and DACT3 protein expression in asthmatic patients compared with normal controls (P<0.05; Fig. 1B) . In addition, DACT1 protein expression was significantly higher than DACT2 and DACT3 expression in asthmatic patients (P<0.05; Fig. 1B) . It is understood that DACT1 is a key regulator of the Wnt signaling pathway, which is closely associated with lung airway remodeling and inflammatory responses (23) . Therefore, these results suggested that DACT1 may be involved in the development of asthma in children.
Effect of DACT1 on the expression of pro-inflammatory factors in RAW264.7 cells.
To further evaluate the role of DACT1 in the development of asthma in children, RAW264.7 cells were used for in vitro analysis. It was identified that DACT1 mRNA expression was significantly increased compared with DACT2 and DACT3 mRNA in RAW264.7 cells (P<0.05; Fig. 2A ). DACT1 expression was significantly inhibited by siR-DACT1 compared to the negative control (P<0.05; Fig. 2B ). Suppression of DACT1 expression significantly decreased the expression of IL13, IL5 and IL6 mRNA compared with the negative control (P<0.05; Fig. 2B ). Additionally, DACT1 expression was significantly enhanced by pcDNA3.1-DACT1 and overexpression of DACT1 significantly increased the expression of IL13, IL5 and IL6 mRNA compared with the empty vector control (P<0.05; Fig. 2C) , with the largest increase in IL6 expression. No significant changes in the expression level of β-catenin mRNA were observed upon DACT1 knockout or overexpression ( Fig. 2B and C) . These results suggested that DACT1 may upregulate the expression of pro-inflammatory factors.
Effect of DACT1 on the expression of β-catenin protein in
Raw264.7 cells. Next, the effect of DACT1 on the protein expression level of β-catenin was investigated. Western blot analysis revealed that DACT1 protein expression was markedly increased compared with DACT2 and DACT3 (Fig. 3A ) in RAW264.7 cells. siR-DACT1 transfection markedly downregulated DACT1 expression, while β-catenin protein expression was increased, compared with the negative control. It is understood that accumulation of β-catenin in the cytoplasm mediates the translocation of β-catenin from the cytoplasm to the nucleus, inducing the expression of multiple genes (24) . Thus, nuclear β-catenin expression was evaluated and it was identified that nuclear β-catenin was upregulated when DACT1 expression was silenced compared with the negative control (Fig. 3B) . Overexpression of DACT1 in RAW264.7 cells downregulated cytoplasmic and nuclear β-catenin levels compared with the empty vector (Fig. 3B) . These results indicated that DACT1 may regulate the expression of pro-inflammatory factors IL13, IL5 and IL6 by modulating the expression and translocation of β-catenin.
DACT1 upregulates the expression of IL13, IL5 and IL6 by downregulating the expression and translocation of β-catenin.
To further demonstrate the effect of DACT1 on the expression of β-catenin, and the subsequent regulation of pro-inflammatory factors, a rescue experiment was performed. RAW264.7 cells were transfected with pcDNA3.1-DACT1 and pcDNA3.1-β-catenin, and the expression levels of DACT1 and β-catenin were confirmed by western blot analysis (Figs. 3B and 4A ). IL13, IL6 and IL5 mRNA expression levels were also evaluated using RT-qPCR. It was demonstrated that overexpression of DACT1 in RAW264.7 cells downregulated β-catenin expression compared with the empty vector ( Fig. 3B) and significantly upregulated IL13, IL6 and IL5 mRNA expression compared with the negative control (P<0.05; Fig. 4B ). However, joint overexpression of β-catenin and DACT1 significantly downregulated expression of these three pro-inflammatory factors, compared with DACT1 overexpression alone (P<0.05; Fig. 4B ). These results further demonstrated that overexpression of β-catenin may inhibit the biological function of DACT1, and upregulation of IL13, IL5 and IL-6 by DACT1 was fulfilled, at least partially, via downregulation of β-catenin.
DACT1 inhibits Wnt signaling pathway activation.
In order to investigate whether DACT1 could inhibit the signaling pathway downstream of Wnt, recombinant Wnt protein, Wnt5A, was added into DMEM and RAW264.7 cells were cultured for another 24 h to examine expression of IL13, IL6 and IL5. It was previously reported that Wnt5 is expressed at high levels in RAW264.7 cells (25) . As a secretory protein, Wnt5A primarily influences adjacent cells by autocrine and paracrine actions. Therefore, Wnt5A was used to activate the Wnt signaling pathway in RAW264.7 cells. Following the addition of Wnt5A, pcDNA3.1-DACT1 transfection markedly repressed cytoplasmic β-catenin expression and the nuclear translocation of β-catenin compared with empty vector transfected cells (Fig. 5A) , while expression of IL13, IL6 and IL5 mRNA was significantly increased compared with the negative control (P<0.05; Fig. 5B ). As nuclear translocation of β-catenin is an important marker of Wnt signaling pathway activation (26) , these results indicated that DACT1 could inhibit the Wnt signaling pathway. Therefore, DACT1 may release the inflammatory factors that were formerly repressed by Wnt, thus promoting local inflammation.
Discussion
In the present study, it was identified that DACT1 gene expression was upregulated in lung biopsies from children with asthma compared with healthy controls. Further evaluation at the molecular level revealed that DACT1 was able to inhibit the expression of β-catenin and its translocation into the nucleus in RAW264.7 cells. DACT1 also inactivated the Wnt signaling pathway, likely through inhibiting the nuclear translocation of β-catenin, leading to the upregulation of inflammatory cytokines IL13, IL5 and IL6. This may be related to the development of asthma in children.
Previous evidence indicates that inflammation has an important role in the development of asthma, and various cytokines secreted by inflammatory cells regulate airway hyperresponsiveness and remodeling (27, 28 (15) demonstrated that DACT1 was a positive regulator of β-catenin; however, the correlation of DACT1 and β-catenin in asthma remains unclear. The present results indicated that upregulation of DACT1 expression could inhibit the expression and nuclear translocation of β-catenin in macrophage cell line, RAW264.7, as well as upregulate the expression of IL13, IL5 and IL6 mRNA. In contrast, inhibition of β-catenin expression in this system significantly suppressed this biological function of DACT1. These results indicated that DACT1 may promote airway inflammation in patients with asthma, thus promoting the development of asthma by regulation of the expression and nuclear translocation of β-catenin.
In conclusion, the present study indicated that DACT1 expression is upregulated in tissues from asthmatic patients.
In vitro experiments demonstrated that silencing the expression of DACT1 promoted the expression and nuclear translocation of β-catenin in RAW264.7 cells, and suppressed the expression of IL13, IL5 and IL6. These findings indicate that DACT1 may be a potential target for alleviating the airway inflammatory response in asthma.
